Allergios
Founded 2020 · 1 known investors
Allergios develops an in-vitro allergy diagnostic that visualizes allergic responses by analyzing how a patient's blood serum induces basophil degranulation, using a disposable microfluidic chip, an optical reader (GranulEye), and AI-based analysis software. The system is aimed at clinicians for diagnosing IgE-mediated allergies, starting with food allergies as an alternative to the food challenge test.
Investors · 1
Frequently asked questions
- What does Allergios do?
- Allergios develops an in-vitro allergy diagnostic that visualizes allergic responses by analyzing how a patient's blood serum induces basophil degranulation, using a disposable microfluidic chip, an optical reader (GranulEye), and AI-based analysis software. The system is aimed at clinicians for diagnosing IgE-mediated allergies, starting with food allergies as an alternative to the food challenge test.
- Who are Allergios's investors?
- Allergios's investors include NLC.